Reviewed by Michael Gill, B. Sc.
Image of Memorial Hermann Hospital in Houston, United States.
Phase-Based Progress Estimates
1
Effectiveness
2
Safety

1for Cancer of Pancreas

18+
All Sexes
Thermal therapy (hyperthermia, or heat) enhances the chemotherapy anti-tumor kill. Thermal therapy by itself also kills cancer cells. Whole-body thermotherapy is a systemic treatment that includes the entire body. By using fever-range whole-body thermal therapy, cancer cells can be treated wherever they are throughout the entire body. In this study, we are testing a combination of fever-range thermal therapy combined with chemotherapy to test: 1) the response of metastatic or advanced pancreas cancer to the combined modality treatment of thermotherapy and selected chemotherapy; 2) whether it helps the body immunity fight the pancreas cancer; and 3) if this treatment is safe for the patient. This study does not offer thermal therapy alone. Any patient with measurable, inoperable or metastatic pancreatic cancer may be treated; however, the they will need to undergo specific medical tests to make sure this treatment would be safe for them. We hypothesize that a combined-modality therapy using fever-range whole-body hyperthermia (FR-WBH; temperature = 40 o C; duration = 6 h), administered in an optimized time/sequence schedule with cisplatin, gemcitabine HCl (gemcitabine), and metronomically administered, low-dose interferon-alpha (IFN-alpha) to patients with inoperable or metastatic pancreas cancer, will, without inducing intolerable toxicity: a.) decrease the pancreatic cancer size; b.) improve quality of life; c.) enhance the immune response against the cancer; d.) increase survival; and e.) allow inoperable pancreatic cancer to be converted to operable disease.
Phase 2
Waitlist Available
Memorial Hermann HospitalJoan M Bull, M.D.
25 Pancreas Cancer Clinical Trials Near Me
Top Hospitals for Pancreas Cancer Clinical Trials
Image of Cross Cancer Institute in Alberta.
Cross Cancer Institute
Edmonton
4Active Trials
17All Time Trials for Pancreas Cancer
1998First Pancreas Cancer Trial
Image of The University of Texas MD Anderson Cancer Center in Texas.
The University of Texas MD Anderson Cancer Center
Houston
3Active Trials
17All Time Trials for Pancreas Cancer
2011First Pancreas Cancer Trial
Top Cities for Pancreas Cancer Clinical Trials
Image of Houston in Texas.
Houston
6Active Trials
The University of Texas MD Anderson Cancer CenterTop Active Site
Image of Nashville in Tennessee.
Nashville
5Active Trials
Sarah Cannon Research InstituteTop Active Site
Most Recent Pancreas Cancer Clinical Trials
Top Treatments for Pancreas Cancer Clinical Trials
Treatment Name
Active Pancreas Cancer Clinical Trials
All Time Trials for Pancreas Cancer
First Recorded Pancreas Cancer Trial
Chemoradiation
2
4
2015
Arm 2 (peptide receptor radionuclide therapy + cytoreductive surgery)
1
1
2023
SGN-BB228
1
1
2022
TC-510
1
1
2022
PT199
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Pancreas Cancer
Treatment
Year
Sponsor
Dapagliflozin
2021
Washington University School of Medicine
MVT-5873
2019
National Cancer Institute (NCI)
Liposomal Irinotecan
2019
Washington University School of Medicine
V941
2019
Merck Sharp & Dohme Corp.
EndoTAG-1
2018
SynCore Biotechnology Co., Ltd.
SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)
2018
Tyme, Inc
Stereotactic Radiation Therapy (SBRT)
2018
Galera Therapeutics, Inc.
Paclitaxel protein-bound
2017
HonorHealth Research Institute
Somatuline Depot
2017
Duke University

What Are Pancreas Cancer Clinical Trials?

According to cancer.gov, pancreatic cancer is a cancer that starts in the pancreas caused by malignant cells forming in the tissues of the pancreas. Clinical trials for Pancreatic cancer are research studies that investigate treatments or a combination of treatments that can benefit those diagnosed with Pancreatic cancer.

The Food and Drug Adminstration reviews and analyzes data from successful clinical trials and determines whether the treatment can be approved for a disease like pancreatic cancer.

Why Is Pancreas Cancer Being Studied Through Clinical Trials?

The World Cancer Research Fund lists pancreatic cancer as the 12th most common forms of cancer worldwide, and those diagnosed with pancreatic cancer have a five-year survival rate. Cancer.net states that an estimated 495,773 people were diagnosed with pancreatic cancer in 2020, and this figure increases by 1% each year.

The American Cancer Association estimates that 62,210 people will be diagnosed with pancreatic cancer in the United States yearly. The average lifetime risk of being diagnosed with pancreatic cancer is 1 in 64, but this number can be affected by certain risk factors.

Clinical trials for pancreatic cancer are necessary because they give patients access to novel treatments. In addition, clinical trials help progress research which leads to better outcomes, and better treatment options for those battling pancreatic cancer.

What Are The Types Of Treatments Available For Pancreas Cancer?

The current treatments used to treat pancreatic cancer include chemotherapy, radiation, surgery, targeted therapy, and immunotherapy.

Some of the most recent clinical trials for pancreatic cancer include:

  1. Plerixafor and Cemiplimab (for the treatment of metastatic pancreatic cancer). The Plerixafor blocks a protein called CXCR4, which is believed to help cancer escape from the immune system. Cemiplimab aids the immune system in helping it recognize and destroy tumor cells.
  2. Elraglusib, Retifanlimab, Gemcitabine, and Nab-Paclitaxel (for treating advanced pancreatic cancer). The combination of these treatments works to shrink tumors in patients with pancreatic cancer.
  3. Retifanlimab (for the treatment of unresectable or metastatic pancreatic cancer). This treatment is for patients with inoperable pancreatic cancer. Retifanlimabhis helps the immune system attack cancer and may prevent new tumors and cancer cells from growing and spreading.

What Are Some Of The Breakthrough Clinical Trials For Pancreas Cancer?

There have been a few breakthrough clinical trials for pancreatic cancer in recent years. Some of these include:

2022: Chemo Immunotherapy Combination – A study of a combination of chemotherapy and immunotherapy is being led by researchers at Perelman School of Medicine and has shown promising results thus far. This treatment is aimed at unleashing the immune system's anticancer capacity and has shown a one-year survival rate of 57.7% compared to 35% when chemotherapy is used alone.

2022: AMP945 – A clinical trial conducted by the Garvan Institute of Medical Research has shown that a new targeted treatment for pancreatic cancer can make tumors more susceptible to chemotherapy and can increase patient survival rates. The AMP945 drug works to help break down the defenses in pancreatic tumors and looks to be a promising treatment for pancreatic cancer.

According to clinicaltrials.gov, one clinical trial that is being studied for those with stage IV pancreatic cancer is the MDX-010 trial. The MDX-010 treatment is a drug treatment that helps immune cells kill cancer cells.

Who Are Some Of The Key Opinion Leaders/Researchers/Institutions Conducting Pancreas Cancer Trial Research?

Steven A. Rosenberg is a key researcher in the MDX-010 treatment for patients with stage IV pancreatic cancer. Steven Rosenberg is widely known in the field of cancer research and clinical trials and has spent 40 years studying immunotherapy treatments for cancer, including pancreatic cancer.

Christopher Wolfgang is a pancreatic cancer researcher and has shown great interest in the biological behavior of pancreatic cancer. He has been an author of 463 peer-reviewed articles in the last 15 years and is well known for his approach to helping pancreatic patients overcome steep odds.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. Review. https://pubmed.ncbi.nlm.nih.gov/314019032 Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Abu Hejleh T, Berg DJ, Zhang J, Keech J, Parekh KR, Bhatia S, Monga V, Bodeker KL, Ahmann L, Vollstedt S, Brown H, Shanahan Kauffman EP, Schall ME, Hohl RJ, Clamon GH, Greenlee JD, Howard MA, Schultz MK, Smith BJ, Riley DP, Domann FE, Cullen JJ, Buettner GR, Buatti JM, Spitz DR, Allen BG. O(2)(⋅-) and H(2)O(2)-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017.02.018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268. https://pubmed.ncbi.nlm.nih.gov/283666793 Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. https://pubmed.ncbi.nlm.nih.gov/233818144 Welsh JL, Wagner BA, van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. https://pubmed.ncbi.nlm.nih.gov/233818145 Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010 Jan 15;16(2):509-20. doi: 10.1158/1078-0432.CCR-09-1713. Epub 2010 Jan 12. https://pubmed.ncbi.nlm.nih.gov/200680726 Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ. GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29. https://pubmed.ncbi.nlm.nih.gov/293831307 Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652. https://pubmed.ncbi.nlm.nih.gov/298462508 Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, Wellik L, Li Y, Krull J, Wenzl K, Novak AJ, Ansell SM, Bishop GA, Billadeau DD, Peng KW, Giles F, Schmitt DM, Witzig TE. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373. doi: 10.1182/blood.2018874560. Epub 2019 May 17. https://pubmed.ncbi.nlm.nih.gov/311016219 Park JA, Santich BH, Xu H, Lum LG, Cheung NV. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release. J Immunother Cancer. 2021 May;9(5). pii: e002222. doi: 10.1136/jitc-2020-002222. https://pubmed.ncbi.nlm.nih.gov/3398612410 Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ, Schmitt DM, Idell S, Tucker TA. Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis. Sci Rep. 2019 Dec 12;9(1):18925. doi: 10.1038/s41598-019-55176-w. https://pubmed.ncbi.nlm.nih.gov/31831767